Science

Our SGK1 development pipeline

Precision medicine through serum- and glucocorticoid-regulated kinase 1 (SGK1) inhibition, across electrical and structural heart disease and beyond.

Program
Discovery Preclinical Phase 1 Phase 2 Phase 3

  • THRV-1268

    LQT2 and LQT3

    Long QT Syndrome Type 2 and Type 3

    FDA Fast Track Designation
    Phase 2/3 · Wave II Enrolling

  • THRV-1268

    HFrEF

    Heart failure with electrical instability

    Phase 2a · ASPIRE-HF Enrolling soon

  • THRV-1268

    Atrial fibrillation (AFib)

  • Next-generation SGK1 inhibitor

    Other cardiovascular diseases

    Preclinical

  • Next-generation SGK1 inhibitors

    Non-CNS diseases

    Discovery

  • Next-generation SGK1 inhibitors

    CNS diseases

    Discovery

Program details

    • Wave II: Phase 2/3 trial enrolling people aged 15 and older with LQTS Type 2 in the United States

    • LQTS Type 3 enrollment in Wave II is anticipated in 2027

    • FDA Fast Track Designation

    Learn more ➜‍ ‍Wave II study ➚

    • Targeting residual risk from pathological electrical and structural remodeling despite guideline-directed medical therapy

    • Human genetic validation of SGK1 in heart failure, plus preclinical data showing superior efficacy versus a leading SGLT2 inhibitor Read the paper

    • Phase 1 data showing robust, clinically meaningful QTc reduction in obese participants Read the paper

    • Phase 2a ASPIRE-HF in HFrEF with QTc prolongation, enrolling soon

    • FDA IND clearance for heart failure

    Learn more ➜‍ ‍ASPIRE-HF study ➚

    • Targeting pathological remodeling in AF to reduce arrhythmia burden and recurrence

    • Atrial SGK1 is upregulated in people with AF and obesity

    • Robust preclinical proof-of-concept data

    Learn more ➜

    • SGK1 activation is implicated in the structural and electrical remodeling that drives cardiomyopathies

    • SGK1-driven structural and electrical remodeling converge across heart failure and cardiomyopathy populations

    Learn more ➜


  • Multiple active discovery and preclinical programs across other cardiovascular diseases, CNS diseases and additional non-CNS indications where SGK1 activation drives disease biology.

The safety and efficacy of THRV-1268 have not been established. THRV-1268 is investigational; these research programs do not establish a treatment benefit. THRV-1268 has not been approved for commercial use by any regulatory authority (e.g., the FDA in the United States, Health Canada in Canada, or the TGA in Australia).